Sun Pharma Board Meeting on Jan 31 to approve Q3 results and interim dividend
Sun Pharma's Board Meeting on January 31, 2026, will approve Q3 FY26 results and consider an interim dividend. The record date for the dividend is February 5, 2026. The trading window closes January 1 and reopens February 2.
The announcement of the board meeting to approve financial results and consider an interim dividend is material information for investors and may influence trading decisions.
The announcement is a routine corporate update regarding a board meeting to approve financial results and consider a dividend. It does not contain information that would significantly alter the company's valuation or outlook.
Sun Pharmaceutical Industries Limited will hold a Board Meeting on Saturday, January 31, 2026. The board will consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. Additionally, the board will consider and approve the declaration of an interim dividend for the financial year 2025-26.
If an interim dividend is declared, the record date for its payment will be Thursday, February 05, 2026. This means that equity shareholders whose names appear on the Register of Members as of this date will be eligible to receive the dividend.
The company will deduct tax at source from dividends paid to shareholders at the prescribed rates. Shareholders are advised to update their information with their depository for shares held in dematerialized form and with MUFG Intime India Pvt. Ltd for shares held in physical form to ensure timely dividend receipt.
Furthermore, in line with a previous communication dated December 29, 2025, the trading window for the company's securities has been closed effective January 01, 2026, and will remain closed until February 02, 2026.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under board meeting. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.